Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on Recursion Pharmaceuticals but lowers the price target from $16 to $11.

September 04, 2024 | 10:22 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst Gil Blum maintains a Buy rating on Recursion Pharmaceuticals but lowers the price target from $16 to $11, indicating a more cautious outlook.
The maintained Buy rating suggests continued confidence in the company's prospects, but the lowered price target reflects a more cautious outlook, possibly due to market conditions or company performance. This mixed signal may result in neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100